FDA's Drug Abuse Advisory Committee
Executive Summary
At its June 4-5 meeting will discuss the rescheduling of glutethamide (Rhone Poulenc Rorer's Doriden); a post marketing proposal for studying the abuse of dezocine (Astra's Dalgan); a committee report on agonist-antagonist opioid analgesics; and interim advisory subcommittee reports on guidelines for the clinical evaluation of drug addiction medications and guidelines for animal and human abuse liability testing. The meeting begins at 9 a.m. in Conference Rooms G and H of FDA's Parklawn Building.